This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
2.Global burden of disease (GBD) for hepatitis C. Journal of Clinical Pharmacology 2004; 44: 20–29.
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine
2006; 144: 705–714.
Hepatitis C virus infection in USA: an estimate of true prevalence. Liver International
2011; 31: 1090–1101.
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American journal of Respiratory and Critical Care Medicine
1998; 157: 1871–1876.
Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest
2007; 131: 803–808.
10.P Baghaei , Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases. American Journal of Therapeutics 2010; 17: 17–22.
11.U Beijer , A Wolf , S Fazel . Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. Lancet Infectious Diseases 2012; 12: 859–870.
12.JJ Saukkonen , An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine 2006; 174: 935–952.
, Intersecting infections of public health significance. Public Health Report. Seattle, WA: HIV/AIDS Epidemiology Program, Public Health – Seattle & King County, 2008.
17.CDC. Reported tuberculosis in the United States, 2010. Atlanta, GA: U.S. Department of Health and Human Services, 2011.
19.HB El-Serag , Association between hepatitis C infection and other infectious diseases: a case for targeted screening? American Journal of Gastroenterology 2003; 98: 167–174.
20.G Friedland . Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. Journal of Acquired Immune Deficiency Syndrome 2010; 55 (Suppl. 1): S37–42.
Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. International Journal of Infectious Diseases
2008; 12: 51–56.
23.MA Pando , Human immunodeficiency virus and tuberculosis in Argentina: prevalence, genotypes and risk factors. Journal of Medical Microbiology 2008; 57: 190–197.
Hepatitis C virus infection in patients with tuberculosis in Central Brazil. International Journal of Tuberculosis and Lung Disease
2011; 15: 1397–1402.
Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. BMC Public Health
2008; 8: 245.
27.K Mitruka , CA Winston , TR Navin . Predictors of failure in timely tuberculosis treatment completion, United States. International Journal of Tuberculosis and Lung Disease 2012; 16: 1075–1082.
28.E Sbrana , Co-morbidities associated with tuberculosis in an autopsy case series. Tuberculosis 2011; 91 (Suppl. 1): S38–42.
. Prisons as social determinants of hepatitis C virus and tuberculosis infections. Public Health Reports
2010; 125 (Suppl. 4): 25–33.
30.CA Winston , K Mitruka . Treatment duration for patients with drug-resistant tuberculosis, United States. Emerging Infectious Diseases 2012; 18: 1201–1202.